4 recruiting, 4 unknown, 2 not yet recruiting. 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Recruiting 4, Unknown 4, Not yet recruiting 2 |
Follow Upper Tract Urothelial Carcinoma: new trials by email Literature Review of Upper Tract Urothelial Carcinoma trials Research Report on Upper Tract Urothelial Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Photodynamic Diagnosis of Upper Tract Urothelial Carcinoma Using Fluorescence Endoscopy and Oral 5-ALA 5-Aminolevulinic acid Hydrochloride (Gliolan®) - Upper Tract Urothelial Carcinoma | Phase 2 | Recruiting | Henry Ford Health System | 10 | 2026-09-15 | 2026-09-18 |
| Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper Tract Urothelial Carcinoma RC48 Combined With Tislelizumab - Upper Tract Urothelial Carcinoma | Phase 2 | Not yet recruiting | RenJi Hospital | 50 | 2026-05-31 | 2026-05-13 |
| NECTAR Study: Neoadjuvant Toripalimab + 9MW2821 for Local UTUC Toripalimab, 9MW2821, Radical Nephroureterectomy with or without Lymph Node Dissection - Upper Tract Urothelial Carcinoma | Phase 2 | Not yet recruiting | Peking University Third Hospital | 40 | 2026-02-01 | 2026-02-17 |
| Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUC Avelumab 10 mg/kg, Screening, Best Supportive Care (BSC) - Upper Tract Urothelial Carcinoma | Phase 2 | Recruiting | Samsung Medical Center | 48 | 2025-09-16 | 2025-11-06 |
| Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC Nab-Paclitaxel, Tislelizumab, Radical nephroureterectomy (RNU) - Upper Tract Urothelial Carcinoma, Neoadjuvant Therapy | Phase 2 | Recruiting | Tianjin Medical University Second Hospital | 35 | 2025-07-05 | 2025-08-17 |
| A Study of RC48-ADC Combined with JS001 for Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma RC48-ADC and JS001 - Carcinoma, Upper Tract Urothelial Carcinoma | Phase 2 | Recruiting | Jinling Hospital, China | 30 | 2022-11-23 | 2025-01-22 |
| Feasibility of Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma RNU, Gemcitabine/Cisplatin, M-VAC Protocol - Upper Tract Urothelial Carcinoma | Phase 2 | Unknown | The European Uro-Oncology Group | 200 | 2018-05-28 | 2023-12-18 |
| Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Nephroureterectomy for Primary Upper Tract Urothelial Carcinoma Patients Pirarubicin - Bladder Recurrence, Upper Tract Urothelial Carcinoma | Phase 2 | Unknown | Peking University First Hospital | 200 | 2016-11-01 | 2016-11-17 |
| Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Diagnostic Ureteroscopy for Primary Upper Tract Urothelial Carcinoma Patients Pirarubicin - Upper Tract Urothelial Carcinoma, Bladder Recurrence | Phase 2 | Unknown | Peking University First Hospital | 200 | 2016-08-01 | 2017-09-21 |
| Prophylactic Intravesical Chemotherapy to Prevent Bladder Tumors After Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinomas pharmorubicin or pirarubicin - Upper Tract Urothelial Carcinoma, Bladder Recurrence | Phase 2 | Unknown | Xuesong Li | 200 | 2015-09-01 | 2015-09-11 |
Carcinoma (1) · Kidney Neoplasms (1) · Pathologic Complete Response (1)
Neoplasms (2) · Disease Attributes (1) · Disease Progression (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Kidney Diseases (1) · Male Urogenital Diseases (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1) · Urologic Diseases (1)
pirarubicin (3) · tislelizumab (2) · 130-nm albumin-bound paclitaxel (1) · Aminolevulinic Acid (1) · Cisplatin (1) · Epirubicin (1) · Gemcitabine (1) · Lymph Node Excision (1) · M-VAC protocol (1) · Mass Screening (1) · avelumab (1) · toripalimab (1)
Peking University First Hospital (2) · Henry Ford Health System (1) · Jinling Hospital, China (1) · Peking University Third Hospital (1) · RenJi Hospital (1) · Samsung Medical Center (1) · The European Uro-Oncology Group (1) · Tianjin Medical University Second Hospital (1) · Xuesong Li (1)
China (6) · Netherlands (1) · Norway (1) · South Korea (1) · Spain (1) · United States (1)
Hailong Hu, PhD (1) · Johar Raza, MD (1) · Susanne Osanto, MD, PhD (1)